Featured Research

from universities, journals, and other organizations

Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer

Date:
December 3, 2008
Source:
Emory University
Summary:
Results from cell culture studies suggest a class of anticancer compounds called EGFR inhibitors, largely written off for breast cancers, could be effective in obese patients. The hormones leptin and IGF-1 synergistically stimulate migration and invasion in breast cancer cells. EGFR inhibitors block this stimulation.

Once-promising drugs that were abandoned in the fight against breast cancer still could be effective in obese patients, new research suggests.

Related Articles


In laboratory tests, hormones produced by fat cells stimulate breast cancer cells to migrate and invade surrounding tissues, scientists at Emory University School of Medicine found. A class of drugs called epithelial growth factor receptor (EGFR) inhibitors could block the stimulatory effects of the hormones.

"This group of compounds was basically written off as far as breast cancer goes," says senior author Dipali Sharma, PhD, assistant professor of oncology/hematology at Emory University School of Medicine and Emory Winship Cancer Institute.

Sharma and her colleagues have been studying the effects of leptin, a hormone produced by adipocytes (fat cells), on breast cancer cells. One of leptin's functions is to send "had enough" signals to the hypothalamus, part of the brain that controls appetite, and it also regulates bone formation, reproductive functions and the growth of blood vessels.

Most obese people appear to produce an abundance of leptin but for them, leptin"s appetite-controlling effects are muted in ways that are poorly understood. In addition to leptin, obese people also have high levels of insulin-like growth factor-1 (IGF-1), which is produced primarily by the liver.

"The influence of obesity on breast cancer is more pronounced because most of the breast tissue is made of adipocytes," Sharma says. "There is an increasing amount of evidence for the importance of the environment surrounding the tumor in spurring its growth."

She and first author Neeraj Saxena, PhD, assistant professor of medicine/digestive diseases, found that together leptin and IGF-1 stimulate breast cancer cells to grow more than either does by itself. Together, they activate the EGFR molecule, the target of several anti-cancer drugs.

"Inhibiting either leptin or IGF-1 by itself would only take care of one," Sharma says. "Instead, we thought it would be better to look downstream and see where the two pathways converge."

Various EGFR inhibitors, such as erlotinib and cetuximab, have been approved by the FDA to treat head and neck cancer, lung cancer, colon cancer and pancreatic cancer. One, lapatinib, was approved in 2007 for women with advanced breast cancer who had already received other therapies.

However, clinical studies did not find most EGFR inhibitors effective against breast cancer for a large enough proportion of patients. Some oncologists believe it may be possible to select a fraction of patients, either through genetics or the characteristics of their tumors, who have a better chance of having the drugs work.

In the laboratory, EGFR inhibitors blocked the stimulatory effects of leptin and IGF-1 and had more of an effect on breast cancer cells' ability to migrate and invade other tissues than on proliferation. This suggests they could blunt aggressive, metastatic tumor behavior, Sharma says.

She says her team's finding could be especially important for "triple negative" breast cancer, a form that does not respond to tamoxifen or the drug trastuzumab. Recent studies have shown a high prevalence of triple negative breast cancer in African-American women.

To strengthen the finding, Sharma is planning more tests in animals that model cancer growth in obese individuals and careful study of leptin and IGF-1 levels in human tumor samples.

The research was funded by the National Institutes of Health, the Wilbur and Hilda Glenn Founation, the Georgia Cancer Coalition, the Susan G. Komen Foundation and the Mary K. Ash Foundation.


Story Source:

The above story is based on materials provided by Emory University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Saxena, N.K. et al. Bidirectional crosstalk between leptin and insulin-like growth factor-1 signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Research, Dec 2008

Cite This Page:

Emory University. "Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer." ScienceDaily. ScienceDaily, 3 December 2008. <www.sciencedaily.com/releases/2008/12/081201195943.htm>.
Emory University. (2008, December 3). Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2008/12/081201195943.htm
Emory University. "Curbing Hormones' Effects In Obese Patients Could Aid Against Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/12/081201195943.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins